Matt Simmons 💊

Oncology Strategy Lead @IQVIA_Biotech. Opinions my own.

[Matt Simmons 💊 @MatthewHSimmons]

LHR > BER ✈️ #ESMO25

[Matt Simmons 💊 @MatthewHSimmons]

MXP > LHR 🛬

[Matt Simmons 💊 @MatthewHSimmons]

Let’s talk…. #ASCO25

[Matt Simmons 💊 @MatthewHSimmons]

LHR > ORD ✈️ #ASCO2025

[Matt Simmons 💊 @MatthewHSimmons]

From innovation to impact...

[Matt Simmons 💊 @MatthewHSimmons]

#RadioLigandTherapy
https://t.co/fqWxXILTnU

[Matt Simmons 💊 @MatthewHSimmons]

Sequencing whole genome of newborns will be ‘transformational’ in earlier diagnosis and treatment of rare diseases...

https://t.co/YebUGcw0R8

[IQVIA Institute @IQVIA_Institute]

📊 Shifts in global clinical trial distribution: Europe's share declines across most segments, while China sees growth, except in biosimilars. More on these regional trends from our Rethinking Clinical Trial Country Prioritization report: https://t.co/QT1YqhDiH3. #ClinicalTrials

[Matt Simmons 💊 @MatthewHSimmons]

What else is needed in the near-term to change the trajectory of the past five years and increase Europe’s share of global oncology trial sites ? #ESMO24

[Matt Simmons 💊 @MatthewHSimmons]

The latest performance data from the UK’s MHRA reveal that clinical trial applications continue to be handled within the target statutory timescales - average of 27 days compared with the statutory timescales of 30 days)
https://t.co/QKUpD7JjHk

[Matt Simmons 💊 @MatthewHSimmons]

https://t.co/4jXBmt4rqy 👍👍

[Matt Simmons 💊 @MatthewHSimmons]

Join me at the @IQVIA_Institute multi-stakeholder symposium ahead of #ESMO24 in Barcelona...

https://t.co/uKEV4Bme3H

[Matt Simmons 💊 @MatthewHSimmons]

It's that time again ! See you in Barcelona... https://t.co/f53UJL34f1

[Matt Simmons 💊 @MatthewHSimmons]

The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing— Challenging the “more is better” dogma https://t.co/CtB6DYlaRC

[Matt Simmons 💊 @MatthewHSimmons]

Noteworthy advances in oncology R&D shared during #ASCO24 enhancing the art of cancer care and potentially transforming treatment approaches for patients... https://t.co/LnTGUX7hRx

[Matt Simmons 💊 @MatthewHSimmons]

https://t.co/rrBOQQVbQx

[Matt Simmons 💊 @MatthewHSimmons]

Although careful consideration is necessary to determine which #clinicaltrials in #oncology are well suited for inclusion of pragmatic design features, there is growing momentum to simplify, broaden access and increase generalizability of study data.... https://t.co/69dfzuccw1

[Matt Simmons 💊 @MatthewHSimmons]

"In Phase I trials, #AI-discovered molecules are substantially more successful than historic industry averages..."

https://t.co/Dx8htaR6xg

[Matt Simmons 💊 @MatthewHSimmons]

#ASCO24 ✅

See you next year !

[Matt Simmons 💊 @MatthewHSimmons]

❓As increasing molecular subtyping continues to turn even some common tumour types a set of rare diseases, is there a way to make just-in-time site activation live up to its promise through reducing the administrative and regulatory burden for sites ?

[Matt Simmons 💊 @MatthewHSimmons]

Some key takeaways:

1️⃣: Multiple targeted agents are available across many different tumours, with many more in development, but most patients just aren’t getting tested and so aren’t getting optimal care…

[IQVIA Institute @IQVIA_Institute]

🔬Happening Now: IQVIA Institute Pre-ASCO Symposium in Chicago & virtually. We are discussing the future of precision oncology, including clinical trial site selection, recruitment challenges, real-world data needs, testing practices, and ensuring patient access. #Oncology

[Matt Simmons 💊 @MatthewHSimmons]

❓How do we turn the real world data often buried in medical notes into real world evidence that is generalizable to bring precision medicine clinical trials to patients ?